Friday, Amedisys Inc. (AMED), provider of home health and hospice services, reaffirmed its guidance for the full year.
Amedisys' reiterated its full-year earnings outlook in the range of $4.75-$4.90 per share, excluding the effects of any possible future acquisitions. The company also backed its service revenue guidance in the range of $1.475 billion to $1.5 billion, for the year.
On average, Analysts polled by Thomson Reuters expect Amedisys to report profit of $4.84 per share for the full year on revenues of $1.5 billion. Analysts typically exclude one-time items.
In July, the company had raised its earnings guidance to the current range of $4.75-$4.90 per share from $4.10 - $4.30 per share issued in January.
AMED is currently trading at $34.04 on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.